Journal
CANCER IMMUNOLOGY RESEARCH
Volume 7, Issue 1, Pages 62-76Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-18-0424
Keywords
-
Categories
Funding
- NIH [R21Al134127]
- Cancer Research UK King's Health Partners Centre at King's College London
- Berlin Institute of Health (BIH) [CRG1-TP1]
Ask authors/readers for more resources
Anticancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines, The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available